{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:49:44Z","timestamp":1785527384284,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Genetic profiling of a new HPV-negative cervical cancer model identified pathogenic variants in genes implicated in oncogenic signaling, cell cycle regulation, and DNA damage repair pathways, including homologous recombination, non-homologous end-joining, and mismatch repair. Deficiencies in\n                    <jats:italic>BRCA<\/jats:italic>\n                    2, RAD51 and MLH1 were among these actionable targets. The newly described cervical cancer model revealed sensitivity towards the PARP inhibitor olaparib, which was further augmented upon combination with platinum-based chemotherapeutics. In contrast,\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    -proficient cervical cancer cells exhibited greater resistance to these strategies. This study highlights the potential of in-depth genetic analysis to identify genetic susceptibilities to guide personalized medicine approaches.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-59964-z","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:32:42Z","timestamp":1785328362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model"],"prefix":"10.1038","volume":"16","author":[{"given":"Robert","family":"Polten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Kutle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Lennart","family":"Stalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hachenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"John-Neek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Seyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanya","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Schmidtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriia","family":"Obrizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Kokem\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Steinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"L\u00fchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Lisa","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"G\u00f6hring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Gronewold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schaudien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Geffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"D\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Klapdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"59964_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"59964_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ijc.25396","volume":"128","author":"N Li","year":"2011","unstructured":"Li, N., Franceschi, S., Howell-Jones, R., Snijders, P. J. F. & Clifford, G. M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int. J. Cancer 128, 927\u2013935 (2011).","journal-title":"Int. J. Cancer"},{"key":"59964_CR3","doi-asserted-by":"publisher","unstructured":"Tommasino, M. The human papillomavirus family and its role in carcinogenesis. Sem. Cancer Biol. 26:13\u201321. https:\/\/doi.org\/10.1016\/j.semcancer.2013.11.002 (2014).","DOI":"10.1016\/j.semcancer.2013.11.002"},{"key":"59964_CR4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose, S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048\u20131056 (2010).","journal-title":"Lancet Oncol."},{"key":"59964_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ygyno.2020.06.506","volume":"158","author":"K Martell","year":"2020","unstructured":"Martell, K. et al. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol. Oncol. 158, 776\u2013784 (2020).","journal-title":"Gynecol. Oncol."},{"key":"59964_CR6","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/cncr.28288","volume":"119","author":"AA Wright","year":"2013","unstructured":"Wright, A. A. et al. Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119, 3776\u20133783 (2013).","journal-title":"Cancer"},{"key":"59964_CR7","doi-asserted-by":"crossref","unstructured":"Yim, E. K. & Park, J. S. The role of HPV E6 and E7 oncoproteins in HPV-associated Cervical Carcinogenesis. Cancer Res. Treat 37 (2005).","DOI":"10.4143\/crt.2005.37.6.319"},{"key":"59964_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41379-019-0249-1","volume":"32","author":"I Nicol\u00e1s","year":"2019","unstructured":"Nicol\u00e1s, I. et al. HPV-negative tumors of the uterine cervix. Mod. Pathol. 32, 1189\u20131196 (2019).","journal-title":"Mod. Pathol."},{"key":"59964_CR9","doi-asserted-by":"publisher","unstructured":"Kokka, F., Bryant, A., Brockbank, E., Powell, M. & Oram, D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Datab. Syst. Rev. 7. https:\/\/doi.org\/10.1002\/14651858.CD010260.pub2 (2015).","DOI":"10.1002\/14651858.CD010260.pub2"},{"key":"59964_CR10","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung, H. C. et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 37, 1470\u20131478 (2019).","journal-title":"J. Clin. Oncol."},{"key":"59964_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl. J. Med. 370, 734\u2013743 (2014).","journal-title":"N Engl. J. Med."},{"key":"59964_CR12","doi-asserted-by":"publisher","unstructured":"Lee, J. E., Chung, Y., Rhee, S. & Kim, T. H. Untold story of human cervical cancers: HPV-negative cervical cancer. BMB Rep. 55:429\u2013438. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.9.042 (2022).","DOI":"10.5483\/BMBRep.2022.55.9.042"},{"key":"59964_CR13","first-page":"135","volume":"32","author":"N Auersperg","year":"1964","unstructured":"Auersperg, N. Long-term cultivation of hypodiploid human tumor cells. J. Natl. Cancer Inst. 32, 135\u2013163 (1964).","journal-title":"J. Natl. Cancer Inst."},{"key":"59964_CR14","first-page":"859","volume":"39","author":"T Yamada","year":"1987","unstructured":"Yamada, T. et al. Establishment and characterization of a cell line (OMC-4) originating from a human adenocarcinoma of the uterine cervix. Nihon Sanka Fujinka Gakkai Zasshi. 39, 859\u2013860 (1987).","journal-title":"Nihon Sanka Fujinka Gakkai Zasshi"},{"key":"59964_CR15","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1128\/JVI.00182-10","volume":"84","author":"JD Suerth","year":"2010","unstructured":"Suerth, J. D., Maetzig, T., Galla, M., Baum, C. & Schambach, A. Self-inactivating alpharetroviral vectors with a split-packaging design. J. Virol. 84, 6626\u20136635 (2010).","journal-title":"J. Virol."},{"key":"59964_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-642-59918-7_9","volume-title":"Diagnostic Cytogenetics","author":"B Schlegelberger","year":"1999","unstructured":"Schlegelberger, B. et al. Classical and Molecular Cytogenetics of Tumor Cells. in Diagnostic Cytogenetics (ed Wegner, R. D.) 151\u2013185 (Springer Berlin Heidelberg, Berlin, Heidelberg, 1999). https:\/\/doi.org\/10.1007\/978-3-642-59918-7_9."},{"key":"59964_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ijc.35221","volume":"156","author":"L Kokem\u00fcller","year":"2025","unstructured":"Kokem\u00fcller, L. et al. Germline variants of homology-directed repair or mismatch repair genes in cervical cancer. Int. J. Cancer 156, 700\u2013710 (2025).","journal-title":"Int. J. Cancer"},{"key":"59964_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/1066527041410418","volume":"11","author":"G Yeo","year":"2004","unstructured":"Yeo, G. & Burge, C. B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11, 377\u2013394 (2004).","journal-title":"J. Comput. Biol."},{"key":"59964_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10689-015-9794-z","volume":"14","author":"M Sagi","year":"2015","unstructured":"Sagi, M. et al. Genetic screening in patients with Retinoblastoma in Israel. Fam. Cancer 14, 471\u2013480 (2015).","journal-title":"Fam Cancer"},{"key":"59964_CR20","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato, S. et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U S A. 100, 8424\u20138429 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"59964_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli, A. O. et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet. 50, 1381\u20131387 (2018).","journal-title":"Nat. Genet."},{"key":"59964_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","volume":"71","author":"E Kotler","year":"2018","unstructured":"Kotler, E. et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol. Cell. 71, 178\u2013190e8 (2018).","journal-title":"Mol. Cell."},{"key":"59964_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","volume":"17","author":"ML Rudd","year":"2011","unstructured":"Rudd, M. L. et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin. Cancer Res. 17, 1331\u20131340 (2011).","journal-title":"Clin. Cancer Res."},{"key":"59964_CR24","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1093\/nar\/15.15.5963","volume":"15","author":"SC Kozma","year":"1987","unstructured":"Kozma, S. C. et al. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res. 15, 5963\u20135971 (1987).","journal-title":"Nucleic Acids Res."},{"key":"59964_CR25","first-page":"8","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim, S. & Jeong, S. Mutation hotspots in the \u03b2-catenin gene: Lessons from the human cancer genome databases. Mol. Cells. 42, 8\u201316 (2019).","journal-title":"Mol. Cells"},{"key":"59964_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jmoldx.2014.06.004","volume":"16","author":"LE MacConaill","year":"2014","unstructured":"MacConaill, L. E. et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J. Mol. Diagn. 16, 660\u2013672 (2014).","journal-title":"J. Mol. Diagn."},{"key":"59964_CR27","unstructured":"Surgical Biopsy Number 92498. Baltimore, MD: Department of Pathology, The Johns Hopkins Hospital. (1951)."},{"key":"59964_CR28","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","volume":"80","author":"M D\u00fcrst","year":"1983","unstructured":"D\u00fcrst, M., Gissmann, L., Ikenberg, H. & zur Hausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. U S A. 80, 3812\u20133815 (1983).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"59964_CR29","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/ijc.30243","volume":"139","author":"C Bodelon","year":"2016","unstructured":"Bodelon, C., Untereiner, M. E., Machiela, M. J., Vinokurova, S. & Wentzensen, N. Genomic characterization of viral integration sites in HPV-related cancers. Int. J. Cancer 139, 2001\u20132011 (2016).","journal-title":"Int. J. Cancer"},{"key":"59964_CR30","doi-asserted-by":"crossref","unstructured":"Bueno-Urquiza, L. J. et al. Phenotypic heterogeneity of cancer associated fibroblasts in cervical cancer progression: FAP as a central activation marker. Cells 13 (2024).","DOI":"10.3390\/cells13070560"},{"key":"59964_CR31","doi-asserted-by":"publisher","unstructured":"Fridman, W. H., Pag\u00e8s, F., Saut\u0300s-Fridman, C. & Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 12:298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245 (2012)","DOI":"10.1038\/nrc3245"},{"key":"59964_CR32","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.2147\/CMAR.S257692","volume":"12","author":"F Guo","year":"2020","unstructured":"Guo, F. et al. Tumor-associated CD163(+) M2 macrophage infiltration is highly associated with PD-L1 expression in cervical cancer. Cancer Manag. Res. 12, 5831\u20135843 (2020).","journal-title":"Cancer Manag Res."},{"key":"59964_CR33","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo, N. et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N. Engl. J. Med. 385, 1856\u20131867 (2021).","journal-title":"N. Engl. J. Med."},{"key":"59964_CR34","doi-asserted-by":"crossref","unstructured":"Kutle, I. et al. Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. Front. Immunol. 15, (2024).","DOI":"10.3389\/fimmu.2024.1485461"},{"key":"59964_CR35","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/cells11233911","volume":"11","author":"AM Evans","year":"2022","unstructured":"Evans, A. M., Salnikov, M., Tessier, T. M. & Mymryk, J. S. Reduced MHC class I and II expression in HPV-negative vs. HPV-positive cervical cancers. Cells 11, 3911 (2022).","journal-title":"Cells"},{"key":"59964_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/ijc.29035","volume":"136","author":"YM Chin","year":"2015","unstructured":"Chin, Y. M. et al. HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. Int. J. Cancer 136, 678\u2013687 (2015).","journal-title":"Int. J. Cancer"},{"key":"59964_CR37","doi-asserted-by":"crossref","unstructured":"Ramachandran, D. & D\u00f6rk, T. Genomic risk factors for cervical cancer. Cancers (Basel) 13 (2021).","DOI":"10.20944\/preprints202109.0441.v1"},{"key":"59964_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.virol.2010.07.044","volume":"407","author":"MS Campo","year":"2010","unstructured":"Campo, M. S. et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407, 137\u2013142 (2010).","journal-title":"Virology"},{"key":"59964_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF01718309","volume":"141","author":"A Hoos","year":"1996","unstructured":"Hoos, A. et al. Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture. Arch. Virol. 141, 449\u2013458 (1996).","journal-title":"Arch. Virol."},{"key":"59964_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1073\/pnas.93.1.479","volume":"93","author":"K Heselmeyer","year":"1996","unstructured":"Heselmeyer, K. et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. U S A. 93, 479\u2013484 (1996).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"59964_CR41","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378\u2013384 (2017).","journal-title":"Nature"},{"key":"59964_CR42","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1130>3.0.CO;2-0","volume":"91","author":"JS Park","year":"2001","unstructured":"Park, J. S. et al. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int. J. Cancer 91, 822\u2013827 (2001).","journal-title":"Int. J. Cancer"},{"key":"59964_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-4608(95)91129-7","volume":"82","author":"DB Zimonjic","year":"1995","unstructured":"Zimonjic, D. B., Simpson, S., Popescu, N. C. & DiPaolo, J. A. Molecular cytogenetics of human papillomavirus-negative cervical carcinoma cell lines. Cancer Genet. Cytogenet. 82, 1\u20138 (1995).","journal-title":"Cancer Genet. Cytogenet."},{"key":"59964_CR44","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1016\/j.ygyno.2024.07.360","volume":"190","author":"MD Ahsan","year":"2024","unstructured":"Ahsan, M. D. et al. HPV-negative cervical cancer: Exploring targetable mutations using next-generation sequencing. Gynecol. Oncol. 190, S246 (2024).","journal-title":"Gynecol. Oncol."},{"key":"59964_CR45","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"RD Burk","year":"2017","unstructured":"Burk, R. D. et al. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378\u2013384 (2017).","journal-title":"Nature"},{"key":"59964_CR46","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.3390\/cancers13184551","volume":"13","author":"FJ Ruiz","year":"2021","unstructured":"Ruiz, F. J. et al. Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers (Basel) 13, 4551 (2021).","journal-title":"Cancers (Basel)"},{"key":"59964_CR47","doi-asserted-by":"publisher","first-page":"50864","DOI":"10.18632\/oncotarget.15140","volume":"8","author":"N Shen","year":"2017","unstructured":"Shen, N. et al. Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: A systematic review and meta-analysis. Oncotarget 8, 50864\u201350872 (2017).","journal-title":"Oncotarget"},{"key":"59964_CR48","doi-asserted-by":"publisher","first-page":"67203","DOI":"10.18632\/oncotarget.18226","volume":"8","author":"S Helbig","year":"2017","unstructured":"Helbig, S. et al. Functional dissection of breast cancer risk-associated TERT promoter variants. Oncotarget 8, 67203\u201367217 (2017).","journal-title":"Oncotarget"},{"key":"59964_CR49","doi-asserted-by":"publisher","first-page":"1133472","DOI":"10.3389\/fcell.2023.1133472","volume":"11","author":"A Ragupathi","year":"2023","unstructured":"Ragupathi, A., Singh, M., Perez, A. M. & Zhang, D. Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. Front. Cell. Dev. Biol. 11, 1133472 (2023).","journal-title":"Front. Cell. Dev. Biol."},{"key":"59964_CR50","doi-asserted-by":"publisher","first-page":"106927","DOI":"10.1016\/j.phrs.2023.106927","volume":"196","author":"Z Phan","year":"2023","unstructured":"Phan, Z., Ford, C. E. & Caldon, C. E. DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review. Pharmacol. Res. 196, 106927 (2023).","journal-title":"Pharmacol. Res."},{"key":"59964_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13046-020-01644-5","volume":"39","author":"S Tian","year":"2020","unstructured":"Tian, S. et al. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. J. Exp. Clin. Cancer Res. 39, 143 (2020).","journal-title":"J. Experimental Clin. Cancer Res."},{"key":"59964_CR52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2024.10.009","volume":"191","author":"SP Elayapillai","year":"2024","unstructured":"Elayapillai, S. P. et al. ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer. Gynecol. Oncol. 191, 182\u2013193 (2024).","journal-title":"Gynecol. Oncol."},{"key":"59964_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ygyno.2019.08.010","volume":"155","author":"A Bianchi","year":"2019","unstructured":"Bianchi, A. et al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol. Oncol. 155, 144\u2013150 (2019).","journal-title":"Gynecol. Oncol."},{"key":"59964_CR54","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/s12885-021-08188-7","volume":"21","author":"E de Castro","year":"2021","unstructured":"de Castro, E. et al. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells. BMC Cancer. 21, 448 (2021).","journal-title":"BMC Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59964-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:12:00Z","timestamp":1785521520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59964-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59964"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59964-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving primary human materials were reviewed and approved by the MHH Ethics Commission (Approval numbers: 6090_BO_K_2018 and 10737_BO_S_2023). The patient provided written informed consent for the use of the material in this study. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23557"}}